Schonfeld Strategic Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20,674	Closed	-$1.69M	–	2657
2025 Q4	$1.69M	Buy	+20,674	New	+$1.54M	0.01%	933
2025 Q3	–	Sell	-32,411	Closed	-$1.31M	–	2572
2025 Q2	$1.31M	Buy	32,411 +19,710	+155%	+$887K	0.01%	1193
2025 Q1	$652K	Buy	12,701 +2,901	+30%	+$143K	﹤0.01%	1471
2024 Q4	$543K	Sell	9,800 -177,713	-95%	-$8.07M	﹤0.01%	1353
2024 Q3	$6.17M	Buy	187,513 +159,376	+566%	+$4.48M	0.04%	466
2024 Q2	$765K	Buy	28,137 +12,606	+81%	+$424K	﹤0.01%	1318
2024 Q1	$565K	Sell	15,531 -163,983	-91%	-$4.82M	﹤0.01%	1436
2023 Q4	$3.64M	Sell	179,514 -64,641	-26%	-$1.08M	0.02%	604
2023 Q3	$4.34M	Buy	+244,155	New	+$4.32M	0.03%	587

Other funds holding TARS

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Schonfeld Strategic Advisors's TARS Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Tarsus Pharmaceuticals (TARS) in Q1 2026, closing a stake of 20,674 shares — an estimated $1.69M sold.

Schonfeld Strategic Advisors first reported a position in TARS in Q3 2023 and held it in 9 quarters. The position peaked at $6.17M in Q3 2024. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

Schonfeld Strategic Advisors reported no remaining Tarsus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Schonfeld Strategic Advisors sold 20,674 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $1.69M.
Schonfeld Strategic Advisors first reported a position in Tarsus Pharmaceuticals in Q3 2023 and held it in 9 quarters.
Schonfeld Strategic Advisors's Tarsus Pharmaceuticals position peaked at $6.17M in Q3 2024.
253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.